

Emily J Henderson Frcp

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2402191/emily-j-henderson-frcp-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26
papers

438
citations

8
h-index

20
g-index

39
ext. papers

658
ext. citations

4.8
avg, IF

3.89
L-index

#	Paper	IF	Citations
26	Parkinson's disease: the nutrition perspective - CORRIGENDUM.. <i>Proceedings of the Nutrition Society</i> , 2022 , 1	2.9	
25	Modelling falls in Parkinson's disease and normal ageing in mice using a complex motor task.. <i>Brain and Neuroscience Advances</i> , 2022 , 6, 23982128221088794	4	
24	Needs of patients with parkinsonism and their caregivers: a protocol for the PRIME-UK cross-sectional study.. <i>BMJ Open</i> , 2022 , 12, e057947	3	
23	Mild and marked executive dysfunction and falls in people with Parkinson's disease. <i>Brazilian Journal of Physical Therapy</i> , 2021 , 25, 437-443	3.7	2
22	Parkinson's disease: the nutrition perspective.. <i>Proceedings of the Nutrition Society</i> , 2021 , 1-15	2.9	2
21	Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease. <i>BMC Neurology</i> , 2021 , 21, 422	3.1	1
20	Rationale and design to evaluate the PRIME Parkinson care model: a prospective observational evaluation of proactive, integrated and patient-centred Parkinson care in The Netherlands (PRIME-NL). <i>BMC Neurology</i> , 2021 , 21, 286	3.1	1
19	Parkinson's disease in older people. <i>Medicine</i> , 2021 , 49, 56-61	0.6	1
18	Fracture Risk Assessment in Atypical Parkinsonian Syndromes. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 385-389	2.2	1
17	The Association Between Frailty and Parkinson's Disease in the ReSPOND Trial. <i>Canadian Geriatrics Journal</i> , 2021 , 24, 22-25	2.8	0
16	Research into ageing and frailty. <i>Future Healthcare Journal</i> , 2021 , 8, e237-e242	0.9	0
15	Current Perspectives on the Assessment and Management of Gait Disorders in Parkinson's Disease. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 2965-2985	3.1	2
14	COVID-19 in older people: a rapid clinical review. <i>Age and Ageing</i> , 2020 , 49, 501-515	3	104
13	Driving in Parkinson's disease: a retrospective study of driving and mobility assessments. <i>Age and Ageing</i> , 2020 , 49, 1097-1101	3	3
12	Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment. <i>BJ Psych Advances</i> , 2020 , 26, 333-342	0.8	3
11	Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. <i>Lancet Neurology, The</i> , 2020 , 19, 623-634	24.1	51
10	Patient-centred management of Parkinson's disease - Authors' reply. <i>Lancet Neurology, The</i> , 2020 , 19, 889-890	24.1	

9	Multimorbidity and Frailty: Tackling Complexity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, S85-S91	5.3	8
8	Proactive and Integrated Management and Empowerment in Parkinson's Disease: Designing a New Model of Care. <i>Parkinson's Disease</i> , 2020 , 2020, 8673087	2.6	14
7	Freezing of Gait in People with Parkinson's Disease: Nature, Occurrence, and Risk Factors. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 631-640	5.3	9
6	Management of fracture risk in Parkinson's: A revised algorithm and focused review of treatments. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 181-187	3.6	10
5	The minimum clinically important difference (MCID) for a falls intervention in Parkinson's: A delphi study. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 106-110	3.6	8
4	Acute inability to mobilise resulting from probable donepezil-induced myoclonus. <i>Age and Ageing</i> , 2018 , 47, 907-908	3	0
3	Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2016 , 15, 249-58	24.1	181
2	Comparison of Test Your Memory and Montreal Cognitive Assessment Measures in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016 , 2016, 1012847	2.6	6
1	The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. <i>BMC Neurology</i> , 2013 , 13, 188	3.1	21